Gastrointestinal diseases are becoming more and more common in developed countries. Therefore, there is an urgent need for human-specific intestinal development and disease models that can recapitulate the structure and function of the gut in vitro. Advances in pluripotent stem cells and primary tissue culture techniques have allowed to culture intestinal epithelial cells that can self-assemble to form intestinal organoids in three-dimensions. These organoids make it possible to establish new, human-specific models to be used to gain insight into gastrointestinal disease and potentially deliver new therapies to treat them.

Human intestinal organoids are millimeter-scale experimental models of the intestinal epithelium. These tissues are grown in the lab by directed differentiation of human pluripotent stem cells (iPSC) and have become the standard for basic and applied biomedical research. Human intestinal organoids are spherical in shape and consist of a liquid-filled space surrounded by a polarized epithelial shell, which mimics the cellular complexity of the intestinal epithelium. The shell is composed of several epithelial lineages, including progenitors, stem cells, and absorptive enterocytes, as well as secretory goblet, enteroendocrine, and Paneth cell precursors. These cells bind to each other through tight junctions, thereby providing a physical barrier between the lumen and the external environment. As in the human gut, the intestinal organoid barrier is dynamic and both actively and passively mediates the transport of molecules and water.

OrganoLab's iPSC-derived intestinal organoids provide a unique in vitro system to simulate the human intestine. These well-established models can be used for determining the effects of novel therapeutic agents on normal intestinal tissue to predict the in vivo responses, usually off-target/off-tissue toxicities. A variety of therapeutic agents can be screened quickly and efficiently, which requires only a small amount of agent and is possible where in vivo screening may be unfeasible.

Benefits

  • Wild-type donor, genetics and karyotype have been verified
  • A variety of cell types including enterocytes, goblet cells, enteroendocrine cells, and Paneth cells have been identified
  • Display multiple key gut markers, CHGA, KRT19, MUC2, OLFM4, and Villin.
  • Show CYP450 induced activities
  • Can be maintained long-term in culture through passaging

References

  1. Fair, Kathryn L. et al.; Intestinal organoids for modelling intestinal development and disease. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373: 20170217.
  2. Nakamura, T. et al.; Advancing Intestinal Organoid Technology Toward Regenerative Medicine. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5(1): 51-60.
  3. Sugimoto S. et al.; Establishment of 3D Intestinal Organoid Cultures from Intestinal Stem Cells. Methods Mol Biol. 2017, 1612: 97-105.
  4. Barkan S. et al.; Long-term flow through human intestinal organoids with the gut organoid flow chip (GOFlowChip). Lab Chip, 2019, 19: 3552-3562.
For research use only. Not for any other purpose.

Online Inquiry

About Us

OrganoLab, now a new branch, is keen to develop organoid models for disease research. Our experienced scientists are working hard to release the full potential of organoids. Many different types of organoid models, such as normal organoid models, tumor organoid models, and organs-on-a-chip, can be used for drug screening or toxicology study. Our expertise in establishing flexible and advanced organoid models will meet the needs of every customer.